Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-01-07
DOI
10.1038/srep19008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application
- (2015) Valentina Sepe et al. Future Medicinal Chemistry
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
- (2015) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands
- (2014) Carmen Festa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dissociation of Intestinal and Hepatic Activities of FXR and LXR Supports Metabolic Effects of Terminal Ileum Interposition in Rodents
- (2013) A. Mencarelli et al. DIABETES
- The TGR5 receptor mediates bile acid–induced itch and analgesia
- (2013) Farzad Alemi et al. JOURNAL OF CLINICAL INVESTIGATION
- Farnesoid X receptor: from medicinal chemistry to clinical applications
- (2012) Stefano Fiorucci et al. Future Medicinal Chemistry
- Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA
- (2011) S. Fiorucci et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist
- (2010) G. Rizzo et al. MOLECULAR PHARMACOLOGY
- Farnesoid X receptor agonists in biliary tract disease
- (2009) Stefano Fiorucci et al. CURRENT OPINION IN GASTROENTEROLOGY
- TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders
- (2009) Atul Tiwari et al. DRUG DISCOVERY TODAY
- FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
- (2009) Sabrina Cipriani et al. JOURNAL OF LIPID RESEARCH
- Bile acid-activated receptors in the treatment of dyslipidemia and related disorders
- (2009) Stefano Fiorucci et al. PROGRESS IN LIPID RESEARCH
- Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders
- (2009) Stefano Fiorucci et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Novel Potent and Selective Bile Acid Derivatives as TGR5 Agonists: Biological Screening, Structure−Activity Relationships, and Molecular Modeling Studies
- (2008) Hiroyuki Sato et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation